H.R. 985 · 116th Congress
FAST Generics Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
WelchSponsor4 cosponsors · 3 D, 1 R
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019
What it does: CRS summary · Introduced in House · Feb 5, 2019
Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019
This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: FAST Generics Act of 2019
Also known as: Fair Access for Safe and Timely Generics Act of 2019
Latest action (Feb 5, 2019): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Feb 5, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.